Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis
Acta Neuropathologica · 2024
DOI: 10.1007/s00401-024-02754-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, 2024. Verfasst von Christina B Schroeter und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Biomarkers, Myasthenia Gravis, Proteinase Inhibitory Proteins, Secretory. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Culture and Science of North Rhine-Westphalia, Forschungskommission of the Medical Faculty of the Heinrich Heine University Düsseldorf, Regierenden Bürgermeister von Berlin - Senatskanzlei Wissenschaft und Forschung.
Abstract (Originalsprache)
Myasthenia gravis is a chronic antibody-mediated autoimmune disease disrupting neuromuscular synaptic transmission. Informative biomarkers remain an unmet need to stratify patients with active disease requiring intensified monitoring and therapy; their identification is the primary objective of this study. We applied mass spectrometry-based proteomic serum profiling for biomarker discovery. We studied an exploration and a prospective validation cohort consisting of 114 and 140 anti-acetylcholine receptor antibody (AChR-Ab)-positive myasthenia gravis patients, respectively. For downstream analysis, we applied a machine learning approach. Protein expression levels were confirmed by ELISA and compared to other myasthenic cohorts, in addition to myositis and neuropathy patients. Anti-AChR-Ab levels were determined by a radio receptor assay. Immunohistochemistry and immunofluorescence of intercostal muscle biopsies were employed for validation in addition to interactome studies of inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3). Machine learning identified ITIH3 as potential serum biomarker reflective of disease activity. Serum levels correlated with disease activity scores in the exploration and validation cohort and were confirmed by ELISA. Lack of correlation between anti-AChR-Ab levels and clinical scores underlined the need for biomarkers. In a subgroup analysis, ITIH3 was indicative of treatment responses. Immunostaining of muscle specimens from these patients demonstrated ITIH3 localization at the neuromuscular endplates in myasthenia gravis but not in controls, thus providing a structural equivalent for our serological findings. Immunoprecipitation of ITIH3 and subsequent proteomics lead to identification of its interaction partners playing crucial roles in neuromuscular transmission. This study provides data on ITIH3 as a potential pathophysiological-relevant biomarker of disease activity in myasthenia gravis. Future studies are required to facilitate translation into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
- Department of Neurology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
- Department of Neuropathology, Charité - Universitätsmedizin Berlin, Bonhoefferweg 3, 10117, Berlin, Germany.
- Department of Neuropaediatrics, Neuromuscular Centre, Universitätsmedizin Essen, Hufelandstr. 55, 45122, Essen, Germany.
- Brain and Mind Center, University of Sydney, 94 Mallett St, Sydney, Australia.
- Department of Neurology, Palacky University Olomouc, Nová Ulice, 779 00, Olomouc, Czech Republic.
ORCID-Profile: Christina B Schroeter
Förderung
- Ministry of Culture and Science of North Rhine-Westphalia
- Forschungskommission of the Medical Faculty of the Heinrich Heine University Düsseldorf
- Regierenden Bürgermeister von Berlin - Senatskanzlei Wissenschaft und Forschung
- Bundesministerium für Bildung und Forschung
- Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Zitieren
APA
Schroeter, C. B., Nelke, C., Stascheit, F., Huntemann, N., Preusse, C., Dobelmann, V., Theissen, L., Pawlitzki, M., Räuber, S., Willison, A., Vogelsang, A., Marina, A. D., Hartung, H. P., Melzer, N., Konen, F. F., Skripuletz, T., Hentschel, A., König, S., Schweizer, M., …, & Ruck, T. (2024). Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis. Acta Neuropathologica. https://doi.org/10.1007/s00401-024-02754-6
Vancouver
Schroeter CB, Nelke C, Stascheit F, Huntemann N, Preusse C, Dobelmann V, et al. Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis. Acta Neuropathologica. 2024. doi:10.1007/s00401-024-02754-6
BibTeX
@article{Schroeter2024,
author = {Schroeter, Christina B and Nelke, Christopher and Stascheit, Frauke and Huntemann, Niklas and Preusse, Corinna and Dobelmann, Vera and Theissen, Lukas and Pawlitzki, Marc and Räuber, Saskia and Willison, Alice and Vogelsang, Anna and Marina, Adela Della and Hartung, Hans-Peter and Melzer, Nico and Konen, Felix F and Skripuletz, Thomas and Hentschel, Andreas and König, Simone and Schweizer, Michaela and Stühler, Kai and Poschmann, Gereon and Roos, Andreas and Stenzel, Werner and Meisel, Andreas and Meuth, Sven G and Ruck, Tobias},
title = {Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis},
journal = {Acta Neuropathologica},
year = {2024},
doi = {10.1007/s00401-024-02754-6}
}
EUVIMED